A Study to Investigate the Effects of Hepatic Impairment on the Pharmacokinetics of PF-07081532
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to characterize the effect of varying degrees of hepatic
impairment on the plasma pharmacokinetics (PK) of PF-07081532 following administration of a
single oral dose of PF-07081532.